title: [Clinical evaluation of transurethral enucleation with bipolar (TUEB)].
abstract: OBJECTIVE
  Transurethral enucleation with bipolar (TUEB) is an established procedure for treating patients with benign prostatic hyperplasia (BPH). In this study, the usefulness of TUEB was evaluated by comparing the preoperative and postoperative results.
  
  
  METHODS
  A total of 45 patients with symptomatic BPH underwent TUEB at our hospital between February 2008 and August 2009. All the patients were assessed using the International prostate symptom score (IPSS), quality of life (QOL) index, overactive bladder symptom score (OABSS), maximum urinary flow rate (Qmax), post void urine residue (PVR), serum prostate specific antigen (PSA) measurement, and estimated prostate weight. Total operative time, enucleation time, enucleated tissue weight, changes in levels of hemoglobin, hematocrit and serum sodium, duration of urethral catheterization, and complications were also investigated. IPSS, QOL index, Qmax, and PVR were reassessed 1, 3, 6 and 12 months after surgery. PSA reduction rate was also assessed 3 months after surgery.
  
  
  RESULTS
  The average age was 71.6 years (60-84 years), estimated prostate weight 53.2 g (11.8-105.6 g), total operative time 125.5 minutes (76-212 min.), enucleation time 96.1 min (56-169 min), enucleated tissue weight 32.3 g (6-82 g), and duration of urethral catheterization 2.5 days (2-7 days). Blood transfusion was not required and hyponatremia was not observed in any patients. IPSS, QOL index, OABSS, PVR, and Qmax were significantly improved 1 month after surgery. As complications, re-catheterisation was reported in 2 patients (4.4%), bladder tanponade in 1 (2.2%), and urinary incontinence requiring at least 1 pad 6 months after surgery in 1 (5.9%). Postoperative PSA declined by 89.8% 3 months after surgery.
  
  
  CONCLUSIONS
  TUEB was a safe and effective treatment procedure for patients with BPH.
authors.affiliation: Department of Urology, Tatebayashi Kosei Hospital.
authors.forename: Hironobu
authors.initials: H
authors.lastname: Okugi
authors.forename: Takeaki
authors.initials: T
authors.lastname: Makino
authors.forename: Haruo
authors.initials: H
authors.lastname: Kato
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Oyam
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Okazaki
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Nakamur
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D011788:Quality of Life; D020728:Transurethral Resection of Prostate / Q000379:methods*; D014563:Urodynamics
chemical_list: D015415:Biomarkers; D017430:Prostate-Specific Antigen